From: Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Author & Year | Regions | No. of patients | Sample | Tested items | Prognosis | Associated clinicopathological parameters | Ref |
---|---|---|---|---|---|---|---|
Perez et al. 2013 | USA | 339 | Preoperative | NLR | RFS (-) | Tumor size, mitotic index | [42] |
Jin et al. 2013 | China | 42 | Preoperative | NLR | OS (-) | Tumor size, mitotic index | [43] |
Atila et al. 2014 | Turkey | 67 | Preoperative | NLR | DFS (-) | NA | [44] |
Kargın et al. 2015 | Turkey | 78 | Preoperative | NLR | OS (-) | Mitotic index | [45] |
Racz et al. 2015 | Canada | 93 | Preoperative | PLR, neutrophils | RFS (-) | Tumor size, mitotic index | [39] |
Goh et al. 2016 | Singapore | 300 | Preoperative | NLR, PLR | RFS (-) | NIH risk, AFIP risk | [46] |
Stotz et al. 2016 | Austria | 149 | Preoperative | PLR | RFS (-) | NA | [47] |
Jiang et al. 2016 | China | 129 | Preoperative | NLR | OS (-) | Tumor stage | [48] |
Feng et al. 2016 | China | 274 | Preoperative | NLR, MLR, PLR, NWR, MWR, low LWR | RFS (-) | Tumor size and location, mitotic index, NIH risk | [49] |
Yin et al. 2017 | China | 400 | Preoperative | PLR | RFS (-) | Tumor size, mitotic index, NIH risk | [50] |
Xue et al. 2017 | China | 510 | Preoperative | NLR | RFS (-) | NA | [51] |
Luo et al. 2018 | Meta | 1676 | Unclear | NLR | DFS (-), RFS (-) | Tumor size, mitotic index, NIH risk | [52] |
Hu et al. 2018 | China | 92 | Preoperative | PLR | RFS (-) | Mitotic index | [53] |
Rutkowski et al. 2018 | Poland | 385 | Imatinib treated | NLR | OS (-), RFS (-) | Mitotic index, driver mutation | [54] |
Liu et al. 2018 | Meta | 1735 | Preoperative | PLR | DFS (-), RFS (-) | Tumor size, mitotic index, NIH risk | [55] |
Zhang et al. 2019 | Meta | 2264 | Unclear | NLR | DFS (-), RFS (-) | Not mentioned | [56] |
Yilmaz et al. 2019 | Turkey | 45 | Unclear | NLR | OS (-) | NA | [57] |
Sun et al. 2019 | China | 431 | Preoperative | NLR, PLR | RFS (-) | NA | [58] |
Sobczuk et al. 2019 | Poland | 146 | Preoperative | NLR | OS (-) | Not associated | [59] |
Yang et al. 2019 | China | 72 | Preoperative | NLR | OS ( +) | Tumor size and location, age | [60] |
Cananzi et al. 2019 | Italy | 127 | Preoperative | MLR, NLR, PLR | DFS (-) | NA | [38] |
Shi et al. 2019 | China | 340 | Preoperative | PNI | RFS ( +) | NIH risk | [61] |
Sun et al. 2020 | China | 85 | Preoperative | NLR | PFS (-), OS (-) | NA | [62] |
Wei et al. 2020 | Meta | 3135 | Unclear | NLR, PLR | DFS (-) | Tumor size, tumor stages, mitotic index | [63] |
Catal et al. 2020 | Turkey | 30 | Preoperative | LMR | NA | AFIP risk score | [64] |
Lin et al. 2020 | China | 424 | Preoperative | PLR | RFS (-) | Not associated | [65] |
Li et al. 2020 | China | 229 | Unclear | NAR | RFS (-) | Not associated | [66] |
Chang et al. 2020 | China | 646 | Preoperative | PLR | DFS (-), OS (-) | Tumor size and location, NIH risk | [67] |
Guo et al. 2020 | China | 143 | Preoperative | Lymphocyte | DFS ( +) | No significant association | [68] |
Yan et al. 2021 | China | 843 | Preoperative | NLR, WLR, MLR, PLR | NA | NIH risk | [69] |
Li et al. 2021 | China | 392 | Preoperative | PNI | RFS ( +) | NA | [70] |
Lu et al. 2021 | China | 160 | Preoperative | SII | RFS (-) | NA | [71] |
Zhao et al. 2022 | China | 591 | Preoperative | HALP | RFS ( +) | Tumor size, site, NIH risk, mitotic index | [72] |
Li et al. 2022 | Meta | 2627 | Preoperative | PNI | RFS ( +) | NA | [73] |
Yang et al. 2022 | China | 455 | Preoperative | CONUT | RFS (-) | Tumor size and location | [74] |
Ding et al. 2023 | China | 57 | Preoperative | SII-PNI | RFS (-) | NA | [75] |